Connect your AI

Exagen Inc. XGN PP&E Sale Proceeds

PP&E Sale Proceeds at other companies

Labcorp HoldingsLH

$7.8M+1,460%

Bio-Rad LaboratoriesBIO

$100K—

RevvityRVTY

——

Other financials

Income statement

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s pp&e sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exagen Inc.'s PP&E sale proceeds?: Exagen Inc. (XGN) reported PP&E sale proceeds of $0 in Q1 2026.
How has Exagen Inc.'s PP&E sale proceeds changed year-over-year?: Exagen Inc.'s PP&E sale proceeds decreased by 100.0% year-over-year, from $6K to $0.
What does PP&E sale proceeds mean?: Cash received from selling property, plant, and equipment no longer needed for operations.